# Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

> **NCT02597101** · PHASE2 · COMPLETED · sponsor: **Nick Giannoukakis, PhD** · enrollment: 14 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Insulin Resistance

## Interventions

- **DRUG:** Metformin
- **DRUG:** saxagliptin
- **DRUG:** AZD9668
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02597101
- **Lead sponsor:** Nick Giannoukakis, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2019-06-10
- **Final completion:** 2019-06-15
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2021-05-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02597101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02597101, "Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02597101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*